Atai Life Sciences Income from Continuous Operations 2020-2024 | ATAI
Atai Life Sciences income from continuous operations from 2020 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Atai Life Sciences Annual Income from Continuous Operations
(Millions of US $) |
| 2023 |
$-44 |
| 2022 |
$-157 |
| 2021 |
$-174 |
| 2020 |
$-179 |
| 2019 |
$-24 |
Atai Life Sciences Quarterly Income from Continuous Operations
(Millions of US $) |
| 2024-09-30 |
$-26 |
| 2024-06-30 |
$-57 |
| 2024-03-31 |
$-27 |
| 2023-12-31 |
$-19 |
| 2023-09-30 |
$43 |
| 2023-06-30 |
$-34 |
| 2023-03-31 |
$-34 |
| 2022-12-31 |
$-47 |
| 2022-09-30 |
$-36 |
| 2022-06-30 |
$-38 |
| 2022-03-31 |
$-38 |
| 2021-12-31 |
$-93 |
| 2021-09-30 |
$-32 |
| 2021-06-30 |
$-53 |
| 2021-03-31 |
$4 |
| 2020-12-31 |
$-94 |
| 2020-09-30 |
$-83 |
| 2020-06-30 |
$-17 |
| 2020-03-31 |
$16 |
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$0.290B |
$0.000B |
|
atai Life Sciences B.V. is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai Life Sciences B.V. is based in BERLIN.
|
